ããªãã¯ããã«ãã
IGFè «çåŠ
ããŒã ããŒãžã«ç§»å
IGFè «çåŠ ã¯ãæå¹æ§ãé«ããå¯äœçšãå°ãªãæšçæããååŠçæ³è¬ãéçºããŠãããã€ãªãã¯ãããžãŒäŒæ¥ã§ãã ã¡ã€ãšãŒã¯ãªããã¯ã§ã®èšåºè©Šéšã§ã¯ãèŽæ»æ§ã®è¡æ¶²ããã«å¯ŸããŠèšåºå¹æãããããšã確èªãããŸããã
IGF Oncology ã¯ãæ¢åã®ååŠçæ³ãšæ¯èŒããŠãæå¹æ§ãé«ããå¯äœçšãå°ãªãæšçæããååŠçæ³è¬ãéçºããŠãããã€ãªãã¯ãããžãŒäŒæ¥ã§ãã åœç€Ÿã®äž»èŠè¬å€ã§ãã IGF-MTX ã¯ãèŽæ»æ§ã®è¡æ¶²ãã MDS ãæšçãšããŠããŸãã çŸåšã¡ã€ãšãŒã¯ãªããã¯ã§èšåºè©Šéšãè¡ãããŠããããããŸã§ã®çµæã¯è¯å¥œã§ã. ç§ãã¡ã¯ãã®è©Šéšã§2人ã®æ£è ããç§ãã¡ã䜿çšããäºå®ã®æäœçšéã§æ²»çããŸããããXNUMXãæã®æ²»çåŸãäž¡æ¹ã®æ£è ã¯æãããªå¯äœçšããªããç æ°ã®ã»ãŒãã¹ãŠã®å°ºåºŠã§æ¹åããŸããã ãããã®æ£è ã¯ã©ã¡ãã以åã®è¬ã§ç æ°ãé²è¡ããŠãããç§ãã¡ã®æ²»çãéå§ããæç¹ã§ã®äœåœã¯3ïœ6ãæã§ããã ããããç§ãã¡ã®è¬ã2ãææçšããåŸãã»ãŒãã¹ãŠã®ç¹ã§æ¹åãããŸããã
IGF-MTXã¯ä»ã®ããã«ãåæ§ã«é©çšã§ããŸãã
æè³ãèããŠããçæ§ãž
ç§ã®ååã¯ãã¥ãŒã»ãã¯ã¿ããã·ã¥ã§ãããããµãã€ããŒãåŒç士ãå士ã§ãã çååŠè ãIGF Oncology ã®åµèšè å Œ CEOã
ãããšã®éç äžã«ãããè¯ãæ²»çæ³ãèæ¡ããIGF Oncology ã®èšç«ã«ã€ãªããã¢ã€ãã¢ãããã«ç¹èš±ååŸããŸããã
ç§ã®çºæã§ãã IGF-MTX ã¯ãè¡æ¶²ããã®éªšé«ç°åœ¢æçå矀 (MDS) ãšéããŸãã MDSãšæŠãããã«äœ¿çšãããŠããçŸåšã®è¬ã¯ããŸãå¹æçã§ã¯ãªããã¡ããã¬ããµãŒãã®ãããªéåžžã®ååŠçæ³è¬ã¯çœè¡çæ°ãåçã«äœäžããããã䜿çšã§ããŸãããMDSæ£è ã¯ãã§ã«è¡çæ°ãéåžžã«äœããããèŽåœçã«ãªãå¯èœæ§ããããŸãã圌ãã®ç æ°ã®ããšã
åœç€Ÿã®ç¹èš±ååŸæžã¿ã®ã€ã³ã¹ãªã³æ§æé·å åããªã¢ã³ãã¿ã³ãã¯è³ªãã¡ããã¬ããµãŒãã«çµåãããããšã«ãããIGF-MTX ãäœæããŸããã 以åã®è¬ã§èŠãããçœè¡çæ°ã®æžå°ã®åé¡ã軜æžããããšã蚌æãããŠããŸãã ããã«ã12åã®XNUMXã®çšéã§ãã¡ããã¬ããµãŒããããå¹æçã§ãã ããã¯ããã®æ²»çæ³ããã现èã«ããç¹ç°çã«çµåãããã现èã®åè£ãåŒãèµ·ããããã现èãæ»æ» ãããããããããã§ãã
ãããŸã§ã®ãšãããIGFã¯åç©è©Šéšãšäººäœè©Šéšã§æåãåããŠããã åœç€Ÿã¯çŸåšãFDA ã®æ¿èªã«åããŠã¡ã€ãšãŒã¯ãªããã¯ã§èšåºè©Šéšãè¡ã£ãŠããŸãã
IGFè «çåŠ ç¹åŸŽ
åœç€Ÿã¯ãå çé ã« 2.00 ãã«ãã 2.50 ãã«ã®äŸ¡æ Œã§æ ªåŒãæäŸããŸãã
以åã®æ ªäŸ¡ 2.00 ãã«ã§ã®å®¹éã¯ãã¹ãŠåãŸããŸããã
ä»ããæè³ããŠçŸåšã®æ ªäŸ¡ 2.05 ãã«ã§ããžã·ã§ã³ãåºå®ããŸããã (å©çšã§ãã容éã«ã¯éãããããŸã)
IGFåµèšè ã¯å士å·ãæã£ãŠããŸãã çååŠè ãåŒç士ãççåè ã ãã€ãªãã¯ãããžãŒã®ããé¢é£äŒæ¥ãèšç«ããã®ã«æé©ãªåè£è ã§ãã
IGFãžã®æè³ã¯å€§å¹ ãªæé·ã®å¯èœæ§ãç§ããŠãããçŸåšæ ªåŒã®è©äŸ¡é¡ã¯ããã10äžãã«ã§ããäžæ¹ãå瀟ã®äž»åå»è¬åã¯å¹Žé200åãã«ãè¶ ããåçã®å¯èœæ§ãèªã£ãŠããã
IGF ã®ç¹èš±ååŸæžã¿ã®ãªãŒãè¬å€ã§ãã IGF-MTX ã¯ãMDS ãã现èãç¹ç°çã«æšçãšããå¯äœçšãéåžžã«äœãããã§ã«åç©å®éšãšããèšåºè©Šéšã§æåããŠããããšã蚌æãããŠããŸãã
IGF-MTX ã¯çŸåšãèŽæ»æ§è¡æ¶²ãã (MDS) ãæ²»çããã¡ã€ãšãŒ ã¯ãªããã¯ã§èšåºè©Šéšäžã§ãã
IGF-MTX ã¯ãçœè¡çæ°ã®æžå°ããŸã£ããåŒãèµ·ãããªããšããç¹ã§ç¬ç¹ã§ãã MDSæ£è ã¯ãã§ã«çœè¡çæ°ã®äœäžã«æ©ãŸãããŠãããããã«æžå°ãããšèŽåœçã«ãªãå¯èœæ§ããããããããã¯éåžžã«éèŠã§ãã
IGF-MTX ã¯ããã现èã«ããç¹ç°çã«çµåããèœåã«å ããŠããã现èã®åè£ãåŒãèµ·ããããã现èãããè匱ã«ããæ»æããããããŸãã
IGFè «çåŠ è¬å€ã®æŠèŠ
- ååŠçæ³è¬ã¡ããã¬ããµãŒãã«çµåããã€ã³ã¹ãªã³æ§æé·å åå€ç°äœã¿ã³ãã¯è³ªã
- ããã§éå°çºçŸããå容äœã¿ã³ãã¯è³ª IGF-1R ãæšçãšããããããã现èãéžæçã«æšçã«ããŠæ»æ» ãããå¥åº·ãªçŽ°èã«ã¯ããŸã圱é¿ãäžããªãæšçååŠçæ³ã§ãã
- åºåœ¢ããã®ããŠã¹ã¢ãã«ã«ãããŠã¯ãã¡ããã¬ããµãŒããããçŽ13åå¹æçã§ãã
- ã¡ããã¬ããµãŒããé垞䜿çšãããæå°çšéã®çŽ12åãšããé©ãã¹ãäœçšéã§å¹æãçºæ®ããŸãã
- æšæºè¬ã§ãããé²è¡ããããžãã³ã¹ãªã³ãè «æ£è ã® XNUMX 人ã¯ãIGF-MTX ã«ããæ²»çåŸã«ããããªããªããŸããã
- ä»ã®XNUMX人ã®åºåœ¢è «çæ£è ã«å¯Ÿããæå¹æ§ã
- æšæºçãªååŠçæ³ã®æãéèŠãªå¯äœçšã§ããè¡çæ°ã®æžå°ã¯ãŒãã§ãã
- 2幎2018æã«ã¡ã€ãšãŒã¯ãªããã¯ã§è¡æ¶²ãã骚é«ç°åœ¢æçå矀ïŒMDSïŒã察象ãšãã第XNUMXaçžèšåºè©Šéšãéå§ã
- MDS ã¯èŽåœçãªè¡æ¶²ã®ããã§ãããããŸãå¹æçãªæ²»çæ³ã¯ãããŸããã
- MDS ã«å¯ŸããŠçŸåšæ¿èªãããŠããè¬ã¯ XNUMX ã€ã ãã§ãããããŸãå¹æããããŸããã
- IGF-MTX ã¯å®éšå®€ã§ MDS 现èã殺ããXNUMX ã€ã®æ¿èªãããè¬å€ã®ãã¡æãäžè¬çã«äœ¿çšããããã®ãšçžä¹å¹æããããŸãã
- IGF å容äœã¯ MDS çŸæ£çŽ°èã§éå°çºçŸããŸãã
- æ£è ã¯è¡çã®æžå°ã«èããããšãã§ãããä»ã®ãã¹ãŠã®çååŠçæ³ãšã¯ç°ãªããIGF-MTX ã¯è¡çã®æžå°ãåŒãèµ·ãããªããããIGF-MTX ã¯ãã®ç æ°ã«éåžžã«é©ããŠããŸãã
MDS ã«ãããã¡ã€ãšãŒå·ã®èšåºè©Šéšçµæ
MDS ã®ã¡ã€ãšãŒèšåºè©Šéšã§æ°ããçµæãåŸãããŸããã èå¿ãªã®ã¯ãã¡ã€ãšãŒã¯ãªããã¯ã®MDSè©Šéšã§è©Šéšããã3人ã®æ£è ã®äž¡æ¹ã«åœç€Ÿã®IGF-MTXè¬ãå¹æããã£ããšããããšã§ãã ãããã®æ£è ã¯æ²»çéå§æã®äœåœã6ïœ2ãæã§ãååã®æ²»çã§ç æ°ãé²è¡ããŠããã ããããåœç€Ÿã®è¬å€ã«ãã XNUMX ãæã®æ²»çåŸãã»ãŒãã¹ãŠã®è¡æ¶²ããã³éªšé«ãã©ã¡ãŒã¿ãäž¡æ¹ãšãæ¹åãããŸããã ããŒã¿ã¯ä»¥äžã®éãã§ãã
骚é«èœççã¯ãã®ç æ°ã®éèŠãªææšã§ãããæåã®è¢«éšè ã§ã¯éªšé«èœççã 22% ãã 5% ã«äžæããæ£åžžç¯å²å ã«ãªããŸããã 2çªç®ã®è¢«éšè ã§ã¯17ïŒ ã§102ãæéäžå®ã®ãŸãŸã§ããããããã¯ç æ°ãå®å®ããŠãããè¬ã®æå¹æ§ã瀺ãææšã§ãã çœè¡çãšå¥œäžçã¯å ç«ç³»æ©èœã® XNUMX ã€ã®éèŠãªãã©ã¡ãŒã¿ã§ãããéåžžããããã®æ£è ãæ»äº¡ãããã®ã¯ææçã§ãã ãããã®ãã©ã¡ãŒã¿ãŒã¯ã©ã¡ãããäž¡æ¹ã®æ£è ã§åçã«æ¹åãããŸããã 被éšè XNUMX ã§è¡å°æ¿ãæžå°ããããšãé€ããŠãä»ã®ãã¹ãŠã®ãã©ã¡ãŒã¿ãŒãäž¡æ¹ã®è¢«éšè ã§æ¹åãŸãã¯å®å®ããŠããŸããã
件å |
101 |
102 |
æ£åžžç¯å² |
||
æç¹ |
ããŒã¹ã©ã€ã³ |
8 é±é |
ããŒã¹ã©ã€ã³ |
8é±é |
|
骚é«ãã©ã¡ãŒã¿ |
|||||
骚é«èœçã®å²å |
22 |
5 |
17 |
17 |
0-5 |
è¡æ¶²åŠãã©ã¡ãŒã¿ |
|||||
çœè¡ç x10(9)/L |
0.8 |
1.8 |
0.8 |
2.9 |
4.5-11 |
èµ€è¡çæ°Ã10(12)/L |
1.92 |
2.38 |
2.72 |
2.79 |
4.1-5.5 |
ãã¢ã°ããã³ (g/dL) |
7.3 |
8.9 |
9.7 |
9.9 |
12-16 |
ãã¢ãã¯ãªãã% |
20.5 |
25.4 |
28.1 |
28.5 |
37-47 |
è¡å°æ¿ x10(9)/L |
12 |
24 |
85 |
39 |
150-450 |
奜äžç x10(9)/L |
0.04 |
0.75 |
0.38 |
1.29 |
2-7 |
ãªã³ãçÃ10(9)/L |
0.71 |
0.87 |
0.38 |
1.4 |
1-3 |
åç x10(9)/L |
0.03 |
0.11 |
0.03 |
0.12 |
0.2-1 |
å¥œé žç x10(9)/L |
0.03 |
0.03 |
0.03 |
0.04 |
0.02-0.5 |
- 人工çã«äœãããé£äžæ¯æ¯çŽ ã
- åµå·£ããããã®ä»ã®ããã§éå°çºçŸããŠããæšçã«çµåããŸãã
- ä»ã®ãã¹ãŠã®è¬å€ãšã¯ç°ãªããåæ段éãããåŸæ段éã®åµå·£ãã现èããããã殺ããããåŸæ段éã®åµå·£ããã«æé©ã§ãã
- èšåºè©Šéšã¯2018幎ã«éå§ãããäºå®ã
IGFè «çåŠ äž»ãªæè³ã®ãã€ã©ã€ã
å€§å¹ ã«æ¹åãããå¯äœçšãããã¡ã€ã«
IGF-MTX è¬ã«ã¯ååŠçæ³ã®ãããªå¯äœçšã¯ã»ãšãã©ãããŸããã ç¹ã«ãè¡çæ°ã®æžå°ãåŒãèµ·ãããŸããã MDSæ£è ã¯ãã§ã«è¡çæ°ãäœãããã以äžã®æžå°ã«ã¯èããããªããããããã¯MDSè¡æ¶²ããã«ãšã£ãŠéåžžã«éèŠã§ãã
åžå ŽèŠæš¡
åœç€Ÿã®äž»èŠå»è¬åã®è²©å£²ã«ããåçã¯ãMDS çŸæ£ã ãã§ç±³åœã ãã§å¹Žé 200 åãã«ãè¶ ãããšæšå®ããŠããŸãã ä»ã®ããã«ãå¿çšå¯èœã§ãã IGFã®200çªç®ã®è¬å€ã§ããCPEã¯ãæ¿èªãããã°åµå·£ããåžå Žã§å¹Žé400åãã«ä»¥äžã®åçãçã¿åºããšäºæž¬ãããŠããã ç·åžå ŽèŠæš¡ã¯å¹ŽéçŽ10åãã«ã«ãªããŸãã IGFã®çŸåšã®è©äŸ¡é¡ã¯çŽ1.9äžãã«ã ããè©äŸ¡é¡ãå€§å¹ ã«äžæããå¯èœæ§ãããã ã€ãå æããã·ã¥ã¯ãããªãã®ãã©ããã¢ã€ã¢ã³ã»ãã«ã¹ã400åãã«ã§è²·åããããããã¯IGFã®å¹Žé売äžé«ãXNUMXåãã«ãšæã ãèããäŸ¡æ Œã«è¿ãã
ä»çµã¿
ããã¯ãMDS è¡æ¶²ãã现èã«é«ã¬ãã«ã§ååšããæšçã§ãã IGF å容äœã«çµåããå¥åº·ãªéªšé«çŽ°èãšã¯å¯Ÿç §çã« MDS è¡æ¶²ãã现èã§éåžžã«ç¹ç°çã«çºçŸãããŸãã ç 究宀㧠MDS è¡æ¶²ãã现èã殺ããŸãã
ã³ã³ã»ããã®èšŒæ
IGF-MTX ã¯ãçã®åç©ã¢ãã«ã«ãããŠãçšéã 13 åäœãå Žåã§ãã¡ããã¬ããµãŒããããå¹æçã§ãã
ã¡ã€ãšãŒã¯ãªããã¯
å瀟ã®IGF-MTXè¬ã¯ã¡ã€ãšãŒã¯ãªããã¯ã§èšåºè©Šéšãè¡ãããŠããã
競äºäžã®åªäœæ§
åœç€Ÿã®ç¹èš±ã«é¢ããç«å Žã¯éåžžã«åŒ·åã§ãã åœç€Ÿã¯ããã®è¬å€ã察象ãšããããã€ãã®ç¹èš±ãçºè¡ããŠããã2035 幎ãŸã§æå¹æéãåããããšã¯ãããŸããããŸãããã®è¬å€ã«ããæ²»çæ¹æ³ã«é¢ããç¹èš±åºé¡ãä¿çäžã§ããã2038 幎ãŸã§ããã«ç¹èš±ãä¿è·ããããšäºæ³ãããŸãã
çŽ 10ååå
æ ªåŒå ¬éåŸã®è©äŸ¡é¡
çŽ 2.25ååå
ç®æšãšããè³æ¬èª¿éé¡
$1,000
æè³å®¶ãããã®æäœé¡
$ 2.00 - $ 2.5
äžæ ªåœããã®äŸ¡æ Œ
IGFè «çåŠ ãããžã¡ã³ã
ããŒãã¡ãã£ã«ã«ãªãã£ãµãŒ
èšåºæ¥å
PPM ãžã®æè³
ç§ãã¡ã¯æäœæè³é¡ 1,000 ãã«ãæäŸããŠãããæ倧 2.25 äžãã«ã調éããããšãç®æšãšããŠããŸãã åå ã«ãèå³ãããããŸãããããä»ããæè³ããã¿ã³ãã¯ãªãã¯ããŠãã ããã 2.00 æ ªããã 2.50 ãã«ãã XNUMX ãã«ã®éã§ããã€ãã®æè³ã¬ãã«ãæäŸãããŠããŸãã å çé ã§ã®ãæäŸãšãªããŸãã
ãã®æè³ã¯äžçäžã®æè³å®¶ã«æäŸãããŸã
ãã㧠PPM ããèªã¿ãã ããã PPM ãååŸãã
IGFè «çåŠ ç¥ç財ç£ã®æŠèŠ
-
ç±³åœç¹èš±ç¬¬ 7,811,982 å·ããã³ 765IGF-MTX ã察象ãšãããã¡ããªãŒ
IGF Oncology ã¯ç±³åœç¹èš±ç¬¬ 7,811,982 å·ãææããŠãããæããååŠçæ³å€ã«çµåãã IGF-1 ã®å€ç°äœãåºãç¹èš±è«æ±ããŠããŸãã IGF-1 ã®å€ç°äœã¯ãå¯æº¶æ§ IGF çµåã¿ã³ãã¯è³ªã«å¯Ÿããçµå芪åæ§ãäœäžãããã®ã§ãã ç¹èš±è«æ±ã®ç¯å²ã¯ã765IGFå€ç°äœããã³765IGF-MTXè€åäœãå å«ãããããã®å称ãŸãã¯é瀺ã¯ããŠããªãã ã¡ããã¬ããµãŒãã¯ãè€åäœã®ååŠçæ³å€éšåãšããŠç¹ã«ç¹èš±è«æ±ãããŠããã ãã®ç¹èš±ã«ã¯USPTOã®é 延ã«å¯Ÿãã770æ¥ã®å»¶é·æéãããã2026幎9,011,880æé ã«æéåããšãªããèšåºè©ŠéšãFDAã®æ¿èªãŸã§ã«å©çšã§ããæéã¯ããã«å»¶é·ãããã ãã®ãã¡ããªãŒã®ä»ã®ç¹èš±ã«ã¯ãç±³åœç¹èš±ç¬¬ 8,501,906 å·ããã³ç¬¬ XNUMX å·ããããŸãã ãã®ãã¡ããªãŒã§ã¯ãã«ãããè±åœããã©ã³ã¹ããã€ããæ¥æ¬ã§å€åœç¹èš±ãååŸããŠããŸãã
-
ç±³åœç¹èš±ç¬¬ 9,675,671 å·ããã³ 765IGF-MTX ããã³ 765EGF-ãã³ãã ã¹ãã³ã察象ãšãããã¡ããªãŒ
ãã®ç¹èš±ã¯ãããããIGF-765ããã³EGFã®åœç€Ÿç¬èªã®å€ç°äœã§ãã765IGFã¿ã³ãã¯è³ªããã³1EGFã¿ã³ãã¯è³ªã察象ãšãã765IGFããã³765EGFã§äœ¿çšãããŠãããã®ãšåããŸãã¯é¢é£ããNæ«ç«¯ã»ã°ã¡ã³ããæã€ä»ã®ãµã€ãã«ã€ã³ã察象ãšããŠããŸãã ãã®ç¹èš±ã¯ 12 幎 2035 æ 765 æ¥ã«æéåããšãªããèšåºè©Šéšãš FDA ã®å¯©æ»ã«è²»ããããæéã®å»¶é·ãå¯èœã§ãã èš±å¯ãããç±³åœåå²ç¹èš±ã¯ã765IGFããã³765EGFãå ·äœçã«ã¯765IGF-MTXããã³XNUMXEGF-ãã³ãã ã¹ãã³ãå«ãååŠçæ³è€åäœãã¯ã¬ãŒã ããŠããã ãã®ãã¡ããªãŒã®å€åœç¹èš±åºé¡ã¯ãæ¥æ¬ãã€ã³ããéåœãã«ããããªãŒã¹ãã©ãªã¢ããšãŒãããã§æåºãããŠããŸãã
-
ç±³åœç¹èš±ç¬¬ 8,017,102 å·ããã³ãã®ãã¡ããªãŒ
ãã®ç¹èš±ã¯ãå¯æº¶æ§IGFçµåã¿ã³ãã¯è³ªã«å¯Ÿããçµå芪åæ§ãäœäžããIGF-1å€ç°äœãšæ¯çŽ (ååŠçæ³å€ãšã¯å¯Ÿç §çã«)ã®è€åäœã䞻匵ããŠããã ãã®ãã¡ããªãŒã®ãã 8,920,777 ã€ã®ç¹èš±ã¯ãç±³åœç¹èš±ç¬¬ XNUMX å·ã§ãã ãã®ãã¡ããªãŒã§ã¯è±åœããã€ãããã©ã³ã¹ã§å€åœç¹èš±ãååŸããŠããŸãã
-
ç±³åœä»®ç¹èš±åºé¡ 62/509,150ã骚é«ç°åœ¢æçå矀ã®æ²»çã« 765IGF-MTX ã䜿çšããæ²»çæ¹æ³ãã«ããŒ
ãã®æ«å®ç¹èš±åºé¡ã¯ã2018 幎ã«éåžžã®ç±³åœå®çšç¹èš±åºé¡ããã³åœéç¹èš±åºé¡ã«å€æãããäºå®ã§ãããããã«ã€ããŠç¹èš±ãçºè¡ããããšãç¹èš±æéã¯å°ãªããšã 2038 幎ãŸã§å»¶é·ãããŸãã
-
ç±³åœç¹èš±ç¬¬ 8,664,184 å·ããã³ãã®ãã¡ããªãŒã¯ããšãŒã«å€§åŠããã³å倧åŠããã©ã€ã»ã³ã¹ãååŸããŠããŸãã ã¢ãŒã«ã³ãœãŒå·ã®ãåµå·£ãããåå®®ãããè ¹èããã®æ²»çã«ããã CPE ã®äœ¿çšãã«ããŒ
ãã®ç¹èš±ã«ã¯ãåµå·£çããã³åå®®çãCPEãŸãã¯ãã®å€ç°äœã§ãå Žåã«ããè ¹èââæäžã«ããæ²»çããããã®CPEã®äœ¿çšãå«ãŸããŠããã ãã®ãã¡ããªãŒã®ä»ã®ç¹èš±ã«ã¯ãç±³åœç¹èš±ç¬¬ 9,702,010 å·ããã³ç¬¬ 8,247,371 å·ããããŸãã æå¹æé㯠12 幎 2025 æ 8,247,371 æ¥ã§ãããèšåºè©Šéšããã³ FDA ã®æ¿èªã®ããã«æéã延é·ãããå¯èœæ§ããããŸãã ç±³åœç¹èš±ç¬¬ 638 å·ã§ããUSPTO ã®é 延ã«å¯Ÿãã 7,927,795 æ¥éã®å»¶é·ãèŠå®ãããŠããŸãã ãããã¯ãã¹ãŠã€ã§ãŒã«å€§åŠããã©ã€ã»ã³ã¹ãååŸããŠããŸãã ç±³åœç¹èš±ç¬¬3å·ã¯ãã¯ããŒãã£ã³-4ãŸãã¯ã¯ããŒãã£ã³-XNUMXãŸãã¯ä»ã®å€ãã®éºäŒåã®éå°çºçŸãæ€åºããããšã«ããåµå·£çã®èšºæãŸãã¯ã¢ãã¿ãªã³ã°ã«é¢ãããã®ã§ããã çºæè ã¯åããµã³ãã£ã³å士ã§ãããå倧åŠã«é å±ãããŠããŸãã ã¢ãŒã«ã³ãœãŒå·ã®ãã®ã§ãããããããã©ã€ã»ã³ã¹ãåããŠããŸãã
ã³ã¡ã³ã
ã³ã¡ã³ããæçš¿